CA3078812A1 - Anticorps anti-glyco-muc1 et leurs utilisations - Google Patents

Anticorps anti-glyco-muc1 et leurs utilisations Download PDF

Info

Publication number
CA3078812A1
CA3078812A1 CA3078812A CA3078812A CA3078812A1 CA 3078812 A1 CA3078812 A1 CA 3078812A1 CA 3078812 A CA3078812 A CA 3078812A CA 3078812 A CA3078812 A CA 3078812A CA 3078812 A1 CA3078812 A1 CA 3078812A1
Authority
CA
Canada
Prior art keywords
antibody
glyco
antigen
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3078812A
Other languages
English (en)
Inventor
Thayer White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GO THERAPEUTICS Inc
Original Assignee
GO THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GO THERAPEUTICS Inc filed Critical GO THERAPEUTICS Inc
Publication of CA3078812A1 publication Critical patent/CA3078812A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des anticorps anti-glyco-MUC1 et des fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement à un variant de glycosylation spécifique du cancer de MUC1, et des protéines de fusion et des conjugués anticorps-médicament associés, ainsi que des acides nucléiques codant pour de telles biomolécules. La présente invention concerne en outre l'utilisation des anticorps, des fragments de liaison à l'antigène, des protéines de fusion, des conjugués anticorps-médicament et des acides nucléiques pour le traitement du cancer.
CA3078812A 2017-10-24 2017-10-24 Anticorps anti-glyco-muc1 et leurs utilisations Pending CA3078812A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/058036 WO2019083506A1 (fr) 2017-10-24 2017-10-24 Anticorps anti-glyco-muc1 et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3078812A1 true CA3078812A1 (fr) 2019-05-02

Family

ID=66247577

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3078812A Pending CA3078812A1 (fr) 2017-10-24 2017-10-24 Anticorps anti-glyco-muc1 et leurs utilisations

Country Status (10)

Country Link
EP (1) EP3700936A4 (fr)
JP (2) JP7358367B2 (fr)
KR (2) KR20230165874A (fr)
CN (1) CN111479828B (fr)
AU (1) AU2017436815A1 (fr)
BR (1) BR112020008001A2 (fr)
CA (1) CA3078812A1 (fr)
IL (1) IL274202A (fr)
MX (1) MX2020004220A (fr)
WO (1) WO2019083506A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796498A (zh) * 2022-01-27 2022-07-29 中国农业大学 抑制muc1糖基化修饰的物质在提高乳腺癌细胞对抗乳腺癌药物的敏感度中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
EP2014302A1 (fr) * 2007-07-12 2009-01-14 Institut Curie Anticorps spécifique à l'antigène Tn pour le traitement du cancer
AU2008332296A1 (en) * 2007-12-05 2009-06-11 Kyowa Hakko Kirin Co., Ltd. Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
EP2281844A1 (fr) * 2009-07-31 2011-02-09 Glycotope GmbH Anticorps MUC 1
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR102262720B1 (ko) * 2014-04-28 2021-06-08 이카가쿠 소우야쿠 가부시키가이샤 항muc1 항체 또는 그의 항원 결합성 단편 및 그 용도

Also Published As

Publication number Publication date
KR20200067885A (ko) 2020-06-12
JP2021510307A (ja) 2021-04-22
EP3700936A1 (fr) 2020-09-02
EP3700936A4 (fr) 2021-05-26
CN111479828B (zh) 2024-07-05
JP7358367B2 (ja) 2023-10-10
KR102608763B1 (ko) 2023-11-30
JP2024001073A (ja) 2024-01-09
MX2020004220A (es) 2020-10-05
BR112020008001A2 (pt) 2020-10-20
IL274202A (en) 2020-06-30
WO2019083506A1 (fr) 2019-05-02
KR20230165874A (ko) 2023-12-05
AU2017436815A1 (en) 2020-04-23
CN111479828A (zh) 2020-07-31

Similar Documents

Publication Publication Date Title
US12065504B2 (en) Anti-glyco-MUC1 antibodies and their uses
US20230126689A1 (en) Anti-glyco-cd44 antibodies and their uses
JP2024001073A (ja) 抗グリコｍｕｃ１抗体およびその使用
AU2022324456A1 (en) Anti-glyco-muc4 antibodies and their uses
JP7541930B2 (ja) 抗グリコｍｕｃ１抗体およびその使用
EP4301782A1 (fr) Anticorps anti-glyco-cd44 et leurs utilisations
AU2022339667A1 (en) Anti-glyco-cmet antibodies and their uses
WO2023034571A1 (fr) Anticorps anti-glyco-lamp1 et leurs utilisations
JP2024531915A (ja) 抗グリコｍｕｃ抗体およびその使用
CN118354788A (zh) 抗糖-muc4抗体及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220901

EEER Examination request

Effective date: 20220901

EEER Examination request

Effective date: 20220901

EEER Examination request

Effective date: 20220901

EEER Examination request

Effective date: 20220901